A soluble basal insulin with a longer and flatter exposure profile couldreduce pharmacodynamic variability, potentially reducing hypoglycemia, have similarefficacy to once-daily basal insulins, simplify dosing regimens, and improve treatmentadherence. The gene discussed is INS; the disease is Hypoglycemia.